You are here

OMS721

FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy

CP Wire

Tue, 10/23/18 - 11:00 pm

thrombotic microangiopathy

FDA Grants Orphan Drug Designation to Omeros’ Treatment for Stem Cell Transplant-Associated Thrombotic Microangiopathy

Tue, 10/23/18 - 09:43 am

thrombotic microangiopathy

Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation

CP Wire

Wed, 08/29/18 - 10:26 am

thrombotic microangiopathy

Omeros Receives Orphan Designation in Europe for Treatment in Hematopoietic Stem Cell Transplantation

Tue, 08/28/18 - 11:53 am

thrombotic microangiopathy

Omeros defends its drug, but still won’t answer basic questions

Stat

Wed, 08/23/17 - 10:19 pm

Omeros Kidney Drug Reports Good Results

Investopedia

Tue, 10/18/16 - 09:21 am

Omeros' Pipeline Is Largely Neglected

Seeking Alpha

Sun, 04/24/16 - 11:56 am

FDA fast-tracks Omeros' kidney drug as company moves into Phase 3 tests

Bizjournals.com

Wed, 03/9/16 - 09:18 am

Omeros Corporation: Another Biotech Bubble In The Making?

Yahoo/Benzinga

Wed, 08/19/15 - 09:26 am

Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.

Motley Fool

Thu, 04/3/14 - 09:21 am

Medicines Company

Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros

Motley Fool

Tue, 03/4/14 - 12:31 pm

prostate cancer

Omeros' OMS721 shows positive Phase 1 clinical trial results

Yahoo/Fly on the Wall

Thu, 11/7/13 - 09:48 am